Pro-ocular (Signal12) evaluation
This report evaluates Pro-ocular (Signal12’s Pro-ocular™) using the Open Targets Platform for the indication and competitive landscape of its target diseases. Pro-ocular is not in the Platform; the following data are drugs and targets the Platform associates with each indication.
This report is for strategic and due-diligence use only; it does not constitute regulatory, medical, or investment advice.
For methodology, see How it’s built.
Data: Open Targets Platform. Pro-ocular context: Signal12. Interpretation: Biotica Bio.
Pro-ocular context (curated)
Pro-ocular™ (Signal12) targets the ophthalmic branch of the trigeminal nerve and supports lacrimal and meibomian function to promote endogenous tear production. Indications include ocular graft-versus-host disease (oGVHD), Sjögren syndrome, and dry eye. Phase 3–ready (oGVHD). Source: Signal12 — Pro-ocular.
Indication space
| Indication | EFO ID | Therapeutic area(s) |
|---|---|---|
| sialolithiasis | EFO_1001180 | gastrointestinal disease |
| Sjogren syndrome | EFO_0000699 | immune system disease; gastrointestinal disease; disorder of visual system |
Competitive landscape (from Open Targets)
Pro-ocular is not in the Platform; the following are drugs the Platform associates with each indication.
sialolithiasis (EFO_1001180): 0 known drug(s) in the Platform. No drug rows returned.
Sjogren syndrome (EFO_0000699): 0 known drug(s) in the Platform. No drug rows returned.
Target / mechanism landscape (from Open Targets)
For each indication, the main Platform-associated targets are listed below. Pro-ocular’s mechanism (neuro/trigeminal, lacrimal) is different from these target-associated mechanisms.
sialolithiasis (EFO_1001180): 443 associated target(s). | Target | Score | |——–|——-| | CTXN3 | 0.353 | | COL27A1 | 0.349 | | SH3BP4 | 0.332 | | TBX3 | 0.331 | | SVIL | 0.331 | | RASGEF1B | 0.329 | | THSD7A | 0.328 | | CDH20 | 0.328 | | DNAH9 | 0.328 | | KANK1 | 0.324 |
Sjogren syndrome (EFO_0000699): 2748 associated target(s). | Target | Score | |——–|——-| | IRF5 | 0.490 | | STAT4 | 0.424 | | GTF2I | 0.387 | | CHRM3 | 0.374 | | ATG2B | 0.372 | | CHRM1 | 0.370 | | TNFRSF13C | 0.367 | | TRMU | 0.362 | | COX7B2 | 0.358 | | RBFOX1 | 0.355 |
Commercial relevance
From the Platform: 0 approved and 0 in-development drug associations across the evaluated indications. Pro-ocular is Phase 3–ready for ocular GVHD and positioned in dry eye and Sjögren syndrome. No drug in the Platform is specifically labelled for ocular GVHD in this dataset. Commercial take: Pro-ocular addresses an unmet niche (especially oGVHD) while overlapping with dry eye and Sjögren competitive space; differentiation is mechanism (neuro/lacrimal) and formulation.
R&D relevance
The Platform highlights targets such as CTXN3, COL27A1, SH3BP4, IRF5, STAT4, GTF2I for these diseases. Pro-ocular’s mechanism (ophthalmic branch of trigeminal nerve, lacrimal/meibomian, endogenous tears) is distinct from these target-associated mechanisms. R&D take: Open Targets supports evaluation of the indication space; Pro-ocular occupies a different mechanism niche (neuro/lacrimal) and is complementary to target-centric R&D.
Data provenance
Report generated from the Open Targets Platform GraphQL API (disease(efoId)). Indications queried: EFO_1001180, EFO_0000699. Data: knownDrugs and associatedTargets per disease. Pro-ocular context from Signal12/Pro-ocular. To re-run: node fetch-pro-ocular.js then node generate-pro-ocular-report.js (optional --from-json and --out).
Data: Open Targets Platform. Pro-ocular context: Signal12. Interpretation: Biotica Bio.